Our innovations

The innovative program of hybrid myocardial revascularisation

Warsaw, October 2013

American Heart of Poland Group began a program of hybrid myocardial revascularisation. The treatment consists of stent implantation during percutaneous coronary intervention as well as anastomosis of the internal thoracic artery to the left anterior descending. In the beginning a small incision is made in the intercostal space (instead of large sternotomy), then the internal thoracic artery is drawn and is used as a bypass. The procedure is performed under videoscope inspection without opening the chest in patients with advanced multivessel coronary artery disease in whom the pharmacological treatment is unsuccessful.

The procedure allows for full myocardial revascularisation in men and women aged over 70 years old with high risk connected with for example recently hospitalisation for heart attack. This innovative method ensures faster convalescence time, shortening the length of hospital stay.

These procedures were performed in a modern AHP hospital in Bielsko-Biała, by a team of cardiologists and cardiac surgeons under the supervision of a cardiologists Prof. Paweł Buszman MD, PhD and cardiac surgeon Prof. Andrzej Bochenek, MD, PhD as well as the Head of the Department of Cardiac Surgery Assoc. Prof. Marek Cisowski, MD, PhD with the participation of the Head of the Department of Cardiology Bogdan Gorycki, MD, PhD, and cardiac surgeon Rafik Aby Samry, MD.


The procedure was performed in patients with acute coronary syndrome and severe multivessel coronary atherosclerosis. Up until now this type of patients were led for multi-stage transcatheter and surgical revascularisation of heart vessels Right now, only one operation is performed without the necessity of further interventions

explains Bogdan Gorycki, MD, PhD.

The procedures were carried out in a modern hybrid operating room that enables better possibilities of treatment by using endovascular and endoscopic techniques that allow for implantation of heart valves, stentgrafts, etc.

Due to the fact that patient does not require separate interventions, and thus multiple hospitalizations, he stays in only one hospital department the risk of complications and the total length of hospital stay is lowered – says Assoc. Prof. Marek Ciskowski.

A huge challenge as well as innovation was to perform these procedures with administration of anticoagulant drugs and dual antiplatelet therapy – adds Prof. Paweł Buszman, MD, PhD, co-founder of American Heart of Poland. It was involved with the risk of bleeding, which was eliminated due to the use of new generation of antiplatelet drugs and new technique of drawing and anastomosis. During the procedure we did not observe significant bleeding and patients did not require blood transfusion, which is essential in the classical approach requiring cardiopulmonary bypass.

Patients had a chance to use that innovative solutions for the treatment of coronary artery disease due to new generation of antiplatelet drugs which are currently being introduced into clinical practice and a modern hybrid operating room that was built and equipped using European Union funds that was raised by American Heart of Poland Group and performed under Innovative Economy Operational Programme, Action 4.5. Support for investments of high importance of the economy.

The published results of treatment programs conducted in AHP are at the same level and in some cases are even better than these published by the best centres in the USA, such as Mayo and Cleveland Clinic. These data confirm that it is not only well equipped but also well-organised medical facility with high-educated medical staff. AHP in Bielsko-Biała belongs to the best of its kind in Poland.

The department in Bielsko-Biała is a part of the Centre for Cardiovascular Research and Development. For many years our specialists have been involved in testing of medical devices, drugs and methods of cardiovascular diseases treatment. Among other things we experiment with methods of local administration of drugs in arterosclerosis treatment, new methods of preventing the reperfusion injury after heart attack as well as methods of cardiac muscle and vessels regeneration after heart attack. We are also trying to develop and test new methods of heart valves repair and transcatheter heart replacement, we are testing also new intravascular stents as well as innovative ways of interventional treatment of hypertension.

Przeczytaj także:

Do góry